Starget Pharma specializes in the development of targeted molecular radiotherapy for advanced metastatic cancers. This innovative approach combines radioactive imaging tracers with targeted radiotherapy to diagnose and treat cancer with high precision. The company focuses on creating radioligands, which are composed of a radionuclide for imaging or treatment and a molecular ligand for targeted delivery. These radioligands enable the precise delivery of radiation to cancer cells while minimizing damage to healthy tissues. Starget Pharma's core technology leverages peptide backbone dynamics to enhance the drugability of these radioligands, making them highly effective in treating cancers such as prostate and neuroendocrine tumors. The company operates in the nuclear oncology market, serving healthcare providers and patients with limited or non-existent treatment options. Starget Pharma generates revenue through the development and commercialization of its proprietary radiopharmaceutical products.

Keywords: radiopharmaceuticals, targeted therapy, cancer treatment, radioligands, nuclear oncology, peptide engineering, precision medicine, metastatic cancer, prostate cancer, neuroendocrine tumors.